The estimated Net Worth of Michael H. Goldstein is at least $1.22 millió dollars as of 28 May 2019. Michael Goldstein owns over 12,000 units of Ocular Therapeutix Inc stock worth over $216,790 and over the last 8 years he sold OCUL stock worth over $0. In addition, he makes $1,007,730 as Chief Medical Officer at Ocular Therapeutix Inc.
Sign up
Michael Goldstein OCUL stock SEC Form 4 insiders trading
Michael has made over 2 trades of the Ocular Therapeutix Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 12,000 units of OCUL stock worth $30,120 on 28 May 2019.
The largest trade he's ever made was buying 12,000 units of Ocular Therapeutix Inc stock on 28 May 2019 worth over $30,120. On average, Michael trades about 2,200 units every 7 days since 2016. As of 28 May 2019 he still owns at least 25,686 units of Ocular Therapeutix Inc stock.
You can see the complete history of Michael Goldstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Goldstein biography
Dr. Michael H. Goldstein M.D. serves as Chief Medical Officer of the Company. Dr. Goldstein previously served as Chief Medical Officer of Applied Genetic Technologies Corp., a biopharmaceutical company with a focus in ophthalmology, from December 2016 until September 2017. Prior to joining Applied Genetic Technologies Corp., he served as Chief Medical Officer and VP, Clinical Research of Eleven Biotherapeutics, a biopharmaceutical company. Dr. Goldstein received a B.A. in Political Economy from Williams College, an M.D. from Northwestern University Medical School, and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.
What is the salary of Michael Goldstein?
As the Chief Medical Officer of Ocular Therapeutix Inc, the total compensation of Michael Goldstein at Ocular Therapeutix Inc is $1,007,730. There are 3 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.
How old is Michael Goldstein?
Michael Goldstein is 53, he's been the Chief Medical Officer of Ocular Therapeutix Inc since 2017. There are 11 older and 4 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.
What's Michael Goldstein's mailing address?
Michael's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 24 CROSBY DRIVE, BEDFORD, MA, 01730.
Insiders trading at Ocular Therapeutix Inc
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer és Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
What does Ocular Therapeutix Inc do?
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
What does Ocular Therapeutix Inc's logo look like?
Complete history of Michael Goldstein stock trades at Applied Genetic Technologies Corp és Ocular Therapeutix Inc
Ocular Therapeutix Inc executives and stock owners
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include:
-
Antony Mattessich,
President, Chief Executive Officer, Director -
Patricia Kitchen,
Chief Operations Officer -
Antony Mattessich,
Pres, CEO & Director -
Michael Goldstein,
Chief Medical Officer -
Donald Notman,
Chief Financial Officer -
Dr. Michael H. Goldstein M.M., M.D., M.B.A.,
Pres of Ophthalmology & Chief Medical Officer -
Patricia Kitchen,
Chief Operating Officer -
Philip C. Strassburger,
Gen. Counsel -
Leslie Williams,
Independent Director -
Charles Warden,
Independent Chairman of the Board -
Suh Hong Seung,
Independent Director -
Bruce Peacock,
Independent Director -
Richard Lindstrom,
Independent Director -
Jeffrey Heier,
Independent Director -
Christopher Brinzey,
Managing Director -
Christopher White,
Senior Vice President, Head of Business and Corporate Development -
Dr. Rabia Gurses Ozden,
Sr. VP of Clinical Devel. -
Scott Corning,
Sr. VP of Commercial -
Tracy Smith,
VP of HR -
Christopher G. White,
Chief Bus. Officer -
William H. Ransone II,
VP of Global Sales & Marketing -
Dr. Peter K. Jarrett Ph.D.,
Chief Scientific Officer -
Donald Notman Jr.,
Chief Financial Officer -
Jaswinder Chadha,
Director -
Jonathan H. Talamo,
Chief Medical Officer -
Charles Andrew Hurley,
Chief Commercial Officer -
James M Garvey,
Director -
James Fortune,
Chief Operating Officer -
Amarpreet Sawhney,
President and CEO -
William J Oshea,
Director -
Eric Ankerud,
See Remarks -
W Bradford Smith,
CFO and Treasurer -
Pravin Dugel,
See Remarks -
Rabia Gurses Ozden,
Chief Medical Officer -
Daniel M Bollag,
Sr. VP Reg. Affairs & Quality -
Kevin F. Hanley,
Sr. VP Technical Operations -
Management Inc. Opaleye,
-
Venture Management Co. V, L...,
-
Ii, L.P.Ascension Health Ve...,
-
Iv, Llcsv Life Sciences Fun...,
-
Venture Capital Iii, L.P.Ve...,
-
Iv, Llcsv Life Sciences Fun...,
-
Road Llc Summer,
-
Merilee Raines,
Director -
Philip C. Strassburger,
General Counsel -
Sanjay Nayak,
Chief Strategy Officer -
Nadia Waheed,
Chief Medical Officer